Search research articles
Contact Us
Filters
Showing results (101-110 of 111) with videos related to
Page
of 12
Sort By:
Cancer
|
May 31, 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
Allyson J Ocean, Alexander N Starodub, Aditya Bardia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Robert M Sharkey, Arnold Brenner, Jack Burton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Caroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
Pierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2017
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
Rebecca Suk Heist, Michael J Guarino, Gregory Masters, et al.
The New England Journal of Medicine
|
February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 111) with videos related to
Sort By:
Page
of 12
Cancer
|
May 31, 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
Allyson J Ocean, Alexander N Starodub, Aditya Bardia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Robert M Sharkey, Arnold Brenner, Jack Burton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Caroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
Pierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2017
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
Rebecca Suk Heist, Michael J Guarino, Gregory Masters, et al.
The New England Journal of Medicine
|
February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.
Page
of 12